News

Health Sciences International, based in Connecticut, aims to conduct quality phase I-IV trial research with key therapeutic areas of focus including cardiology, vascular disorders, CNS, endocrinology and internal

In the Connection trial, Dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function. Dimebon was

CancerTYPE ID is a diagnostic test which predicts cancer origin in patients whose primary cancer was initially ‘unknown or uncertain’ using conventional diagnostics. Knowing the site where the

Aspen’s facility manufactures Penems and Penicillins and was originally divested to Aspen in 2007, at the time when company exited from Latam operations. The facility is forecasted to

As per the terms of the collaboration, to-BBB is expected to work with scientists at the GSK R&D centre in Shanghai, China, to further evaluate the brain delivery

GSK’s MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic) candidate is currently being evaluated as an adjuvant treatment in melanoma biopsy specimens in the Phase III clinical study Derma. To be

Intas intends to launch a double-blind, placebo-controlled Phase 3 clinical trial of ABI’s orally administered interferon-alpha lozenges in India before the end of March. The study will involve

The new Thermo Scientific Accela 1250 pump features Force Feedback Control (FFC) which eliminates the need for pulse dampening while improving flow accuracy and gradient precision under extreme

The new SEZ center represents a strategic investment for Kendle and demonstrates its commitment to further invest in Asia/Pacific to meet customer needs. The new unit is expected